Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Feb. 23, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021. "While COVID continues to impact communities around the country and health systems are strained, YUPELRI saw the highest quarter of net sales since its launch," said Rick E Winningham, Chief Executive Officer.

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Bausch Health Companies Inc

BioMarin Pharmaceutical

Clovis Oncology

Global Blood Therapeutics

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet

Patterson-UTI Energy

Select Energy Services

Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.

3 Best Stocks to Buy Right Away for Earnings Acceleration

DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2021 financial results and provide a business update after market close on Wednesday, February 23, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.

Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced enrollment of the first patient in a Phase 4 study of YUPELRI ® (revefenacin) inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Success in this study is intended to capture more of YUPELRI's addressable market and further strengthen its competitive advantage.

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study

DUBLIN, Jan. 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will present as follows:  J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, at 12:00 pm ET (9:00 am PT/5:00 pm GMT) Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events.

Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?

Theravance Biopharma Inc (NASDAQ: TBPH) has voluntarily discontinued its Phase 2 study of izencitinib (gut-selective oral pan-JAK inhibitor) in Crohn's disease (Study 0173).  The decision follows the planned review of trial data by the independent data monitoring committee, which determined concerns about the ongoing benefit-risk of continuing the trial.

Theravance Biopharma Pulls Plug On Izencitinib Crohn's Disease Trial

Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.

Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2021 Results - Earnings Call Transcript

DUBLIN, Nov. 3, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter of 2021. "This last month has been about executing on our strategy to create a new Theravance Biopharma, focused on leveraging expertise in developing and commercializing respiratory therapeutics.

Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know

DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), will report its third quarter 2021 financial results and provide a business update after market close on Wednesday, November 3, 2021. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/9:00 pm IST) that day.

Theravance Biopharma to Report Third Quarter 2021 Financial Results November 3, 2021

The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 51.5% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%.

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

The biotech is not enjoying a winning streak with its pipeline drugs.

Why Theravance Biopharma Stock Dived 16% Today

The stock price of Theravance Biopharma Inc (NASDAQ: TBPH) decreased by over 19% pre-market. This is why it happened.

TBPH Stock: Why It Significantly Decreased Today

Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November and the remainder in February 2022. The Company sees a total annualized operating expense savings of approximately $165 million in 2022 and expects a positive cash flow beginning in 2H of 2022.

Why Are Theravance Bio Shares Plummeting Premarket Today?

Theravance Biopharma Inc. shares TBPH, -6.73% slid 34% in premarket trade Wednesday, after the company announced a major overhaul of its business including reducing its headcount by about 75%, or 270 jobs. The company is also cutting two long-term directors from its board and will focus its R&D effort on its core respiratory assets.

Theravance Biopharma shares slide 34% premarket on news to cut 75% of workforce in strategic overhaul

DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced strategic actions to focus on leveraging its expertise in developing and commercializing respiratory therapeutics in order to maximize shareholder value.

Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio

DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept, 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from a Phase 3 randomized, double-blind, placebo-controlled multi-center Phase 3 study assessing the safety and efficacy of ampreloxetine compared to placebo for the treatment of symptomatic neurogenic orthostatic hypotension (nOH).

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a 7% stake in Theravance Biopharma Inc. ( TBPH , Financial) earlier this week.

Steven Cohen Boosts Health Care Exposure With Theravance Biopharma Stake

Amarin Corporation Plc

Arcturus Therapeutics

Arena Pharmaceuticals

bluebird bio

Cassava Sciences Inc

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.

News for Theravance Biopharma Stock (TBPH)